Autologous mesenchymal stem cell therapy for diabetic men with erectile dysfunction. Is it promising? A pilot study

Arch Ital Urol Androl. 2023 Nov 21;95(4):11669. doi: 10.4081/aiua.2023.11669.

Abstract

Purpose: to assess safety and efficacy of autologous mesenchymal bone marrow stem cell injection in penile cavernosal tissue for erectile dysfunction therapy in diabetic men.

Methods: The subjects of this study were diabetic men suffering erectile dysfunction, non-responding to maximum dose of oral PDE5I. Mesenchymal bone marrow stem cells were aspirated and injected after preparation in both corpora cavernosa at 3, 9 o'clock position. Erectile function was assessed by the International Index of Erectile Function and penile Doppler study, before and after 6 months after injection.

Results: 4 patients out of 10 achieve hard erection adequate for satisfactory coitus, and 2 patients achieved penile hardness with addition of pharmacological therapy with sildenafil 100mg. Peak systolic velocity increased significantly in 4 patients (2 arteriogenic and 2 mixed erectile dysfunction), from 12∼22 cm/s to 32∼69 cm/s. Variations in end-diastolic velocity increased substantially in 2 patients with venogenic insufficiency alone at follow-up from 4∼5 cm /s to -4∼-3 cm/s.

Conclusions: Despite promising stem cell treatment efficacy for patients with erectile dysfunction, more clinical studies and researches are still warranted.

MeSH terms

  • Diabetes Mellitus*
  • Erectile Dysfunction* / drug therapy
  • Erectile Dysfunction* / therapy
  • Humans
  • Male
  • Mesenchymal Stem Cell Transplantation*
  • Penile Erection
  • Penis
  • Pilot Projects